Levi & Korsinsky Reminds Cytokinetics, Incorporated Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of November 17, 2025 - CYTK

CYTK investors may also contact Joseph E. Levi, Esq. via email at [email protected] or by telephone at (212) 363-7500. CASE DETAILS: According to the complaint, defendants made materially false and misleading statements regarding the timeline for the New Drug Application ("NDA") submission and approval process for aficamten. Specifically, defendants represented that the Company expected approval from the U.S. Food and Drug Administration ("FDA") for its NDA for aficamten in the second half of 2025, base ...